{
    "clinical_study": {
        "@rank": "48562", 
        "acronym": "FABLORA", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo for the realization of the facial block and morphine for intraoperative analgesia"
            }, 
            {
                "arm_group_label": "Levobupivacaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia"
            }
        ], 
        "brief_summary": {
            "textblock": "A bilateral facial block (infraorbital and infratrochlear) will be performed immediately\n      after intubation in patients undergoing outpatient rhinoplasty with 2.5% levobupivacaine\n      (intervention group) or saline as control. Intravenous saline or morphine will be\n      administered at the end of surgery in intervention or control groups, respectively. In case\n      of pain in post-anesthesia care unit (numerical pain score >3 on a 0-10 scale), both groups\n      will receive intravenous morphine titration. The total perioperative morphine consumption\n      (intraoperative and in post-anesthesia care unit) will be compared between groups. Pain\n      intensity, presence of nausea/vomiting and patient's satisfaction will be compared between\n      groups."
        }, 
        "brief_title": "Facial Block for Outpatient Rhinoplasty Analgesia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Outpatient Rhinoplasty", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatient rhinoplasty\n\n          -  American Society of Anesthesiologists (ASA) classification I-II\n\n          -  Affiliated to Social Security\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Allergy to levobupivacaine\n\n          -  Incapacity to give consent\n\n          -  Chronic pain"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872728", 
            "org_study_id": "2012.774", 
            "secondary_id": "2012-005831-97"
        }, 
        "intervention": {
            "arm_group_label": [
                "Control", 
                "Levobupivacaine"
            ], 
            "description": "Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine", 
            "intervention_name": "Bilateral facial block after general anesthesia before surgery", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Levobupivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "facial block", 
            "levobupivacaine", 
            "regional anesthesia", 
            "rhinoplasty", 
            "outpatient"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lyon", 
                    "country": "France"
                }, 
                "name": "H\u00f4pital Edouard Herriot"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Facial Block for Outpatient Rhinoplasty Analgesia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "At the end of post-anesthesia care unit stay", 
            "measure": "Total morphine consumption during the perioperative period (operating theater and post-anesthesia care  unit)", 
            "safety_issue": "No", 
            "time_frame": "J0"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "0-10 numerical rating scale (NRS) : from 0 = no pain to 10 = worst pain imaginable", 
                "measure": "Pain intensity in post-anesthesia care unit", 
                "safety_issue": "No", 
                "time_frame": "J0 (At arrival in post-operative care unit)"
            }, 
            {
                "description": "Presence or absence of nausea/vomiting", 
                "measure": "Postoperative nausea and vomiting", 
                "safety_issue": "No", 
                "time_frame": "J1 (At day 1 after surgery)"
            }, 
            {
                "description": "0-3 scale (0 = bad, 1 = poor, 2 = good, 3 = excellent)", 
                "measure": "Patient satisfaction at day 1", 
                "safety_issue": "No", 
                "time_frame": "J1 (At day 1 after surgery)"
            }
        ], 
        "source": "Hospices Civils de Lyon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospices Civils de Lyon", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}